SERPING1在肿瘤免疫微环境重塑与恶性进展中的作用
SERPING1 in Tumor Immune Microenvironment Remodeling and Malignant Progression
DOI: 10.12677/acm.2026.1672720, PDF,    科研立项经费支持
作者: 方志俊, 张道畅, 孙 欣：绍兴大学医学院，浙江 绍兴；沈建江：嵊州市人民医院(浙江大学医学院附属第一医院嵊州分院)检验科，浙江 绍兴；张丽红*：绍兴市人民医院医学检验科，浙江 绍兴
关键词: SERPING1；C1酯酶抑制剂；补体系统；肿瘤免疫微环境；生物标志物；SERPING1； C1 Esterase Inhibitor； Complement System； Tumor Immune Microenvironment； Biomarker
摘要: C1酯酶抑制剂(C1INH)是由SERPING1基因编码的，是补体系统经典途径和凝集素途径的重要负调节因子，也参与了接触系统、凝血和纤溶系统的调节。虽然该基因的功能缺失长期以来被认为是遗传性血管性水肿(HAE)的主要致病因素，但是近些年来，越来越多的证据表明，SERPING1在肿瘤发生发展中具有重要的生物学功能。本文对SERPING1/C1INH在肿瘤生物学中起到的多重作用做了系统的综述，主要从它抑制补体级联反应水平来重塑肿瘤免疫微环境、干预细胞内关键信号通路影响细胞存活状态、调节肿瘤相关炎症反应三个方面进行阐述。此外，根据SERPING1在各种肿瘤类型中表达的异质性以及患者预后相关性，本文对它作为生物标志物和治疗靶点的临床转化前景进行评价。
Abstract: C1 esterase inhibitor (C1INH), encoded by the SERPING1 gene, is a key negative regulator of the classical and lectin pathways of the complement system, and also participates in the regulation of the contact system, coagulation, and fibrinolysis. Although loss-of-function mutations of this gene have long been recognized as the major pathogenic factor of hereditary angioedema (HAE), accumulating evidence in recent years has indicated that SERPING1 plays important biological roles in tumor initiation and progression. This article provides a systematic review of the multiple roles of SERPING1/C1INH in tumor biology, primarily elaborating on three aspects: its remodeling of the tumor immune microenvironment through inhibiting the complement cascade, its intervention in key intracellular signaling pathways to influence cell survival status, and its regulation of tumor-related inflammatory responses. Furthermore, based on the heterogeneous expression of SERPING1 across various tumor types and its correlation with patient prognosis, this review evaluates its clinical translational potential as a biomarker and therapeutic target.
文章引用：方志俊, 张道畅, 孙欣, 沈建江, 张丽红. SERPING1在肿瘤免疫微环境重塑与恶性进展中的作用[J]. 临床医学进展, 2026, 16(7): 1942-1949. https://doi.org/10.12677/acm.2026.1672720

参考文献

[1] Drouet, C., López-Lera, A., Ghannam, A., López-Trascasa, M., Cichon, S., Ponard, D., et al. (2022) SERPING1 Variants and C1-INH Biological Function: A Close Relationship with C1-INH-HAE. Frontiers in Allergy, 3, Article 835503. [Google Scholar] [CrossRef] [PubMed]
[2] Davis, A.E., Mejia, P. and Lu, F. (2008) Biological Activities of C1 Inhibitor. Molecular Immunology, 45, 4057-4063. [Google Scholar] [CrossRef] [PubMed]
[3] Busse, P.J. and Christiansen, S.C. (2020) Hereditary Angioedema. New England Journal of Medicine, 382, 1136-1148. [Google Scholar] [CrossRef] [PubMed]
[4] Santacroce, R., D’Andrea, G., Maffione, A.B., Margaglione, M. and d’Apolito, M. (2021) The Genetics of Hereditary Angioedema: A Review. Journal of Clinical Medicine, 10, Article 2023. [Google Scholar] [CrossRef] [PubMed]
[5] Ponard, D., Gaboriaud, C., Charignon, D., Ghannam, A., Wagenaar‐Bos, I.G.A., Roem, D., et al. (2020) SERPING1 Mutation Update: Mutation Spectrum and C1 Inhibitor Phenotypes. Human Mutation, 41, 38-57. [Google Scholar] [CrossRef] [PubMed]
[6] Haslund, D., Ryø, L.B., Seidelin Majidi, S., Rose, I., Skipper, K.A., Fryland, T., et al. (2019) Dominant-Negative SERPING1 Variants Cause Intracellular Retention of C1 Inhibitor in Hereditary Angioedema. Journal of Clinical Investigation, 129, 388-405. [Google Scholar] [CrossRef] [PubMed]
[7] Hujová, P., Souček, P., Grodecká, L., Grombiříková, H., Ravčuková, B., Kuklínek, P., et al. (2020) Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema through Pseudoexon Activation. Journal of Clinical Immunology, 40, 435-446. [Google Scholar] [CrossRef] [PubMed]
[8] Revel, M., Daugan, M., Sautés-Fridman, C., Fridman, W. and Roumenina, L. (2020) Complement System: Promoter or Suppressor of Cancer Progression? Antibodies, 9, Article 57. [Google Scholar] [CrossRef] [PubMed]
[9] Artero, M.R., Minery, A., Nedelcev, L., Radanova, M. and Roumenina, L.T. (2025) Complement and the Hallmarks of Cancer. Seminars in Immunology, 78, Article ID: 101950. [Google Scholar] [CrossRef] [PubMed]
[10] Zeerleder, S. (2011) C1-Inhibitor: More than a Serine Protease Inhibitor. Seminars in Thrombosis and Hemostasis, 37, 362-374. [Google Scholar] [CrossRef] [PubMed]
[11] Defendi, F., Amen, A., Clavarino, G. and Dumestre-Pérard, C. (2025) C1 Inhibitor: From Complement System to Bradykinin Angioedema. Current Opinion in Immunology, 97, Article ID: 102653. [Google Scholar] [CrossRef] 
[12] Ghebrehiwet, B., Kaplan, A.P., Joseph, K. and Peerschke, E.I.B. (2016) The Complement and Contact Activation Systems: Partnership in Pathogenesis beyond Angioedema. Immunological Reviews, 274, 281-289. [Google Scholar] [CrossRef] [PubMed]
[13] Kaplan, A.P. and Joseph, K. (2010) The Bradykinin-Forming Cascade and Its Role in Hereditary Angioedema. Annals of Allergy, Asthma & Immunology, 104, 193-204. [Google Scholar] [CrossRef] [PubMed]
[14] Lu, F., Fernandes, S.M. and Davis, A.E. (2013) The Effect of C1 Inhibitor on Myocardial Ischemia and Reperfusion Injury. Cardiovascular Pathology, 22, 75-80. [Google Scholar] [CrossRef] [PubMed]
[15] Corrales, L., Ajona, D., Rafail, S., Lasarte, J.J., Riezu-Boj, J.I., Lambris, J.D., et al. (2012) Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. The Journal of Immunology, 189, 4674-4683. [Google Scholar] [CrossRef] [PubMed]
[16] Roumenina, L.T., Daugan, M.V., Petitprez, F., Sautès-Fridman, C. and Fridman, W.H. (2019) Context-Dependent Roles of Complement in Cancer. Nature Reviews Cancer, 19, 698-715. [Google Scholar] [CrossRef] [PubMed]
[17] Busse, P. and Kaplan, A. (2022) Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. The Journal of Allergy and Clinical Immunology: In Practice, 10, 716-722. [Google Scholar] [CrossRef] [PubMed]
[18] Shen, Y., Dong, X., Li, X., Shi, Z., Shao, T., Jiang, J., et al. (2025) WNT Inhibitor SP5-Mediated SERPING1 Suppresses Lung Adenocarcinoma Progression via TSC2/mTOR Pathway. Cell Death & Disease, 16, Article No. 103. [Google Scholar] [CrossRef] [PubMed]
[19] Hsieh, C.C., Wu, Y.H., Chen, Y.L., Wang, C.I., Li, C.J., Liu, I.H., et al. (2025) SERPING1 Reduces Cell Migration via ERK‐MMP2‐MMP‐9 Cascade in Sorafenib‐ Resistant Hepatocellular Carcinoma. Environmental Toxicology, 40, 318-327. [Google Scholar] [CrossRef] [PubMed]
[20] Wei, H.T., Luo, X.L., Lv, F., Deng, H.W., Tang, L.P., Li, K.Z., et al. (2026) Tumor-Associated Macrophage-Specific SERPING1 Contributes to M1-Phenotype Transition and Suppress Colorectal Cancer Tumorigenesis via NF-κB Pathway. International Journal of Biological Macromolecules, 340, Article ID: 150144. [Google Scholar] [CrossRef] 
[21] Cai, S., Dole, V.S., Bergmeier, W., Scafidi, J., Feng, H., Wagner, D.D., et al. (2005) A Direct Role for C1 Inhibitor in Regulation of Leukocyte Adhesion. The Journal of Immunology, 174, 6462-6466. [Google Scholar] [CrossRef] [PubMed]
[22] Reis, E.S., Mastellos, D.C., Ricklin, D., Mantovani, A. and Lambris, J.D. (2018) Complement in Cancer: Untangling an Intricate Relationship. Nature Reviews Immunology, 18, 5-18. [Google Scholar] [CrossRef] [PubMed]
[23] Balduit, A., Vidergar, R., Zacchi, P., Mangogna, A., Agostinis, C., Grandolfo, M., et al. (2023) Complement Protein C1q Stimulates Hyaluronic Acid Degradation via gC1qR/HABP1/p32 in Malignant Pleural Mesothelioma. Frontiers in Immunology, 14, 1151194. [Google Scholar] [CrossRef] [PubMed]
[24] Peng, S., Du, T., Wu, W., Chen, X., Lai, Y., Zhu, D., et al. (2018) Decreased Expression of Serine Protease Inhibitor Family G1 (SERPING1) in Prostate Cancer Can Help Distinguish High-Risk Prostate Cancer and Predicts Malignant Progression. Urologic Oncology: Seminars and Original Investigations, 36, 366.e1-366.e9. [Google Scholar] [CrossRef] [PubMed]
[25] Chouaib, S., Noman, M.Z., Kosmatopoulos, K. and Curran, M.A. (2017) Hypoxic Stress: Obstacles and Opportunities for Innovative Immunotherapy of Cancer. Oncogene, 36, 439-445. [Google Scholar] [CrossRef] [PubMed]
[26] Vito, A., El-Sayes, N. and Mossman, K. (2020) Hypoxia-driven Immune Escape in the Tumor Microenvironment. Cells, 9, Article 992. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, Z., Shen, X., Tan, Z., Mei, Y., Lu, T., Ji, Y., et al. (2023) Interferon Gamma-Related Gene Signature Based on Anti-Tumor Immunity Predicts Glioma Patient Prognosis. Frontiers in Genetics, 13, Article 1053263. [Google Scholar] [CrossRef] [PubMed]
[28] Afshar-Kharghan, V. (2017) The Role of the Complement System in Cancer. Journal of Clinical Investigation, 127, 780-789. [Google Scholar] [CrossRef] [PubMed]
[29] Kajdácsi, E., Jandrasics, Z., Veszeli, N., Makó, V., Koncz, A., Gulyás, D., et al. (2020) Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients. Frontiers in Immunology, 11, Article 794. [Google Scholar] [CrossRef] [PubMed]
[30] Hurler, L., Toonen, E.J.M., Kajdácsi, E., van Bree, B., Brandwijk, R.J.M.G.E., de Bruin, W., et al. (2022) Distinction of Early Complement Classical and Lectin Pathway Activation via Quantification of C1s/C1-INH and MASP-1/C1-INH Complexes Using Novel ELISAs. Frontiers in Immunology, 13, Article 1039765. [Google Scholar] [CrossRef] [PubMed]
[31] Macor, P., Capolla, S. and Tedesco, F. (2018) Complement as a Biological Tool to Control Tumor Growth. Frontiers in Immunology, 9, Article 2203. [Google Scholar] [CrossRef] [PubMed]
[32] Osther, K., Förnvik, K., Liljedahl, E., Salford, L.G. and Redebrandt, H.N. (2019) Upregulation of C1-Inhibitor in Pancreatic Cancer. Oncotarget, 10, 5703-5712. [Google Scholar] [CrossRef] [PubMed]
[33] Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A. and Lambris, J.D. (2019) Complementing the Cancer-Immunity Cycle. Frontiers in Immunology, 10, Article 774. [Google Scholar] [CrossRef] [PubMed]
[34] Obtułowicz, K., Książek, T., Bogdali, A., Dyga, W., Czarnobilska, E. and Juchacz, A. (2020) Genetic Variants of SERPING1 Gene in Polish Patients with Hereditary Angioedema Due to C1 Inhibitor Deficiency. Central European Journal of Immunology, 45, 301-309. [Google Scholar] [CrossRef] [PubMed]

为你推荐